



Universiteit
Leiden
The Netherlands

Immunity in atherosclerosis: novel assays, biomarkers and therapeutic approaches

Grievink, H.W.

Citation

Grievink, H. W. (2023, October 26). *Immunity in atherosclerosis: novel assays, biomarkers and therapeutic approaches*. Retrieved from <https://hdl.handle.net/1887/3655349>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3655349>

Note: To cite this publication please use the final published version (if applicable).

LIST OF PUBLICATIONS

Smit V, de Mol J, Schaftenaar FH, Depuydt MAC, Postel RJ, Smeets D, Verheijen FWM, Bogers L, van Duijn J, Verwilligen RAF, **Grievink HW**, Bernabé Kleijn MNA, van Ingen E, de Jong MJM, Goncalves L, Peeters JAHM, Smeets HJ, Wezel A, Polansky JK, de Winther MPJ, Binder CJ, Tsiantoulas D, Bot I, Kuiper J, Foks AC. Single-cell profiling reveals age-associated immunity in atherosclerosis. *Cardiovasc Res.* 2023 Jun 30;cvad099. doi: 10.1093/cvr/cvad099.

den Heijer JM, Cullen VC, Pereira DR, Yavuz Y, de Kam ML, **Grievink HW**, Moerland M, Leymarie N, Khatri K, Sollomoni I, Spitalny L, Dungeon L, Hilt DC, Justman C, Lansbury P, Groeneveld GJ. A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls. *Mov Disord.* 2023 May;38(5):783-795. doi: 10.1002/mds.29360.

In 't Veld AE*, **Grievink HW***, van der Plas JL, Eveleens Maarse BC, van Kraaij SJW, Woutman TD, Schoonakker M, Klarenbeek NB, de Kam ML, Kamerling IMC, Jansen MAA, Moerland M. Immunosuppression by hydroxychloroquine: mechanistic proof in in vitro experiments but limited systemic activity in a randomized placebo-controlled clinical pharmacology study. *Immunol. Res.* 2023 Feb 22:1-11. doi: 10.1007/s12026-023-09367-3. **shared authors*

Saghari M, Gal P, **Grievink HW**, Klaassen ES, Itano A, McHale D, Moerland M. Impact of oral administration of single strain *Lactococcus lactis* spp. cremoris on immune responses to keyhole limpet hemocyanin immunization and gut microbiota: A randomized placebo-controlled trial in healthy volunteers. *Front Immunol.* 2022 Dec 7;13:1009304. doi: 10.3389/fimmu.2022.1009304.

Grievink HW, Smit V, Huisman BW, Gal P, Yavuz Y, Klerks C, Binder CJ, Bot I, Kuiper J, Foks AC, Moerland M. Cardiovascular risk factors: The effects of ageing and smoking on the immune system, an observational clinical study. *Front Immunol.* 2022 Sep 15;13:968815. doi: 10.3389/fimmu.2022.968815.

Saghari M, Gal P, Gilbert S, Yateman M, Porter-Brown B, Brennan N, Quarantino S, Wilson R, **Grievink HW**, Klaassen ES, Bergmann KR, Burggraaf J, van Doorn MBA, Powell J, Moerland M, Rissmann R. OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005. *Clin Pharmacol Ther.* 2022 May;111(5):1121-1132. doi: 10.1002/cpt.2539.

Buters TP, Hameeteman PW, Jansen IME, van Hindevoort FC, Ten Voorde W, **Grievink HW**, Schoonakker M, de Kam ML, Gilroy DW, Feiss G, Rissmann R, Jansen MAA, Burggraaf J, Moerland M. Clinical, cellular, and molecular effects of corticosteroids on the response to intradermal lipopolysaccharide administration in healthy volunteers. *Clin Pharmacol Ther.* 2022 Apr;111(4):964-971. doi: 10.1002/cpt.2516.

Grievink HW, Smit V, Verwilligen RAF, Bernabe Kleijn MNA, Smeets D, Binder CJ, Yagita H, Moerland M, Kuiper J, Bot I, Foks AC. Stimulation of the PD-1 pathway decreases atherosclerotic lesion development in LDLR deficient mice. *Front Cardiovasc Med.* 2021 Nov 1;8:740531. doi: 10.3389/fcvm.2021.740531.

Buters TP, Hameeteman PW, Jansen IME, van Hindevoort FC, Ten Voorde W, Florencia E, Osse M, de Kam ML, **Grievink HW**, Schoonakker M, Patel AA, Yona S, Gilroy DW, Lubberts E, Damman J, Feiss G, Rissmann R, Jansen MAA, Burggraaf J, Moerland M. Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteers. *Br J Clin Pharmacol.* 2022 Feb;88(2):680-690. doi: 10.1111/bcp.14999.

den Heijer JM, Kruithof AC, van Amerongen G, de Kam ML, Thijssen E, **Grievink HW**, Moerland M, Walker M, Been K, Skerlj R, Justman C, Dudgeon L, Lansbury P, Cullen VC, Hilt DC, Groeneveld GJ. A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator. *Br J Clin Pharmacol.* 2021 Sep;87(9):3561-3573. doi: 10.1111/bcp.14772.

Jacobse J, Ten Voorde W, Tandon A, Romeijn SG, **Grievink HW**, van der Maaden K, van Esdonk MJ, Moes DJAR, Loeff F, Bloem K, de Vries A, Rispens T, Wolbink G, de Kam M, Ziaqkos D, Moerland M, Jiskoot W, Bouwstra J, Burggraaf J, Schrier L, Rissmann R, Ten Cate R. Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial. *Br J Clin Pharmacol.* 2021 Aug;87(8):3162-3176. doi: 10.1111/bcp.14729.

Grievink HW, Gal P, Ozsvar Kozma M, Klaassen ES, Kuiper J, Burggraaf J, Binder CJ, Moerland M. The effect of a 13-valent conjugate pneumococcal vaccine on circulating antibodies against oxidized LDL and phosphorylcholine in man, a randomized placebo-controlled clinical trial. *Biology (Basel).* 2020 Oct 22;9(11):345. doi: 10.3390/biology9110345.

Grievink HW, Jirka SMG, Woutman TD, Schoonakker M, Rissmann R, Malone KE, Feiss G, Moerland M. Antimicrobial peptide omiganan enhances interferon responses to endosomal toll-like receptor ligands in human peripheral blood mononuclear cells. *Clin Transl Sci.* 2020 Sep;13(5):891-895. doi: 10.1111/cts.12789.

In 't Veld AE, **Grievink HW**, Saghari M, Stuurman FE, de Kam ML, de Vries APJ, de Winter BCM, Burggraaf J, Cohen AF, Moerland M. Immunomonitoring of tacrolimus in healthy volunteers: The first step from PK- to PD-based therapeutic drug monitoring? *Int J Mol Sci.* 2019 Sep 23;20(19):4710. doi: 10.3390/ijms20194710.

Grievink HW*, Heuberger JAAC*, Huang F, Chaudhary R, Birkhoff WAJ, Tonn GR, Mosesova S, Erickson R, Moerland M, Haddick PCG, Scarce-Levie K, Ho C, Groeneveld GJ. DNL104, a centrally penetrant RIPK1 inhibitor, inhibits RIP1 kinase phosphorylation in a randomized phase I ascending dose study in healthy volunteers. *Clin Pharmacol Ther.* 2020 Feb;107(2):406-414. doi: 10.1002/cpt.1615. *shared authors

Tran TAT*, **Grievink HW***, Lipinska K, Klufft C, Burggraaf J, Moerland M, Tasev D, Malone KE. Whole blood assay as a model for in

vitro evaluation of inflammasome activation and subsequent caspase-mediated interleukin-1 beta release. *PLoS One*. 2019 Apr 8;14(4):e0214999. doi: 10.1371/journal.pone.0214999. *shared authors

Grievink HW, Moerland M. Sample aging profoundly reduces monocyte responses in human whole blood cultures. *J Immunol Res*. 2018 Jun 5;2018:8901485. doi: 10.1155/2018/8901485.

Grievink HW, Luisman T, Moerland M, Kluit C, Malone KE. Comparison of three isolation techniques for human peripheral blood mononuclear cells: cell recovery and viability, population composition, and cell functionality. *Biopreserv Biobank*. 2016 Oct;14(5):410-415. doi: 10.1089/bio.2015.0104.

Gerritsen J, Fuentes S, **Grievink W**, van Niftrik L, Tindall BJ, Timmerman HM, Rijkers GT, Smidt H. Characterization of *Romboutsia ilealis* gen. nov., sp. nov., isolated from the gastro-intestinal tract of a rat, and proposal for the reclassification of five closely related members of the genus *Clostridium* into the genera *Romboutsia* gen. nov., *Intestinibacter* gen. nov., *Terrisporobacter* gen. nov. and *Asaccharospora* gen. nov. *Int J Syst Evol Microbiol*. 2014 May;64(Pt 5):1600-1616. doi: 10.1099/ijs.0.059543-0.

Curriculum Vitae

Wieke Grievink werd geboren op 31 mei 1986 in Lichtenvoorde. In juni 2003 behaalde zij haar HAVO-diploma aan het Schaersvoorde in Aalten. In datzelfde jaar begon zij aan de studie Biologie & Medisch Laboratoriumonderzoek aan het Saxion college in Enschede. Tijdens deze studie deed ze twee stages, de eerste aan het Universitair Medisch Centrum Groningen, de tweede aan de Wageningen Universiteit bij de afdeling Microbiologie onder begeleiding van dr. S. Fuentes en prof. dr. H. Smidt. Deze stage werd afgerond met het verslag 'Isolation and characterization of an unknown *Clostridium* species from the gastro-intestinal tract of a rat'. Na het behalen van haar Bachelortitel in 2007 heeft ze op diverse laboratoria als analist gewerkt: in 2008 bij Sanquin op het Onderzoek & Ontwikkelingslab, van november 2008 tot februari 2013 bij Crossbeta Biosciences in Utrecht (productie van stabiele A β 1-42 oligomeren), en vanaf 2013 tot april 2016 bij Good Biomarker Sciences te Leiden, waar ze laboratoriumanalyses uitvoerde voor klinische onderzoeken. Vanaf juni 2016 is ze werkzaam bij Centre for Human Drug Research (CHDR) als Bioanalytical Scientist. In oktober 2018 is ze begonnen als promovenda bij het CHDR onder begeleiding van dr. M. Moerland en prof. dr. J. Burggraaf, en de afdeling BioTherapeutics van het Leiden Academic Centre for Drug Research onder begeleiding van dr. A.C. Foks, dr. I. Bot en prof. dr. J. Kuiper.